Drugs / GC5107
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04565015 | Dec 2020 → May 2026 overdue | immunodeficiency disease | GC Biopharma Corp | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02783482 | Oct 2016 → Jul 2019 | immunodeficiency disease | Green Cross Corporation | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC5107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04565015 ↗ |
| Modality | Protein / enzyme biologic | “GC5107, a new 10% liquid intravenous immunoglobulin (IVIG)” PMID 34305948 ↗ Jul 2021 |
| Route | Intravenous | “GC5107 20g/200mL, intravenously, dose of 300 - 900 mg/kg” NCT02783482 ↗ |